Effect of semaglutide on arrhythmic, major cardiovascular, and microvascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis.

Despite the lack of statistical significance, this observed reduction reflects a favorable trend toward improved microvascular outcomes with semaglutide and is clinically relevant, as the prevention of microvascular outcomes is a critical concern in the management of T2D.

also in 932 other papers

For new or worsening nephropathy, subcutaneous semaglutide did not significantly reduce the risk (RR 0.83, 95% CI 0.61 to 1.12), but it had a borderline significance compared with placebo (RR 0.81, 95% CI 0.66 to 1.00).

also in 3,545 other papers

Although our meta-analysis did not reach statistical significance for this outcome either, the subgroup trend we observed suggests that semaglutide may reduce the progression of other microvascular outcomes (new or worsening nephropathy), especially in long-term treatment.

also in 60,398 other papers